Table 2 Immunological monitoring in melanoma patients
Patient No. | HLA | Tumor antigen, HLA expression | ELISPOT | Tetramer | Th1/Th2 balance |
|---|---|---|---|---|---|
1 | A*2402 | 3/5(Tyr,M1,M2), A24(+) | 3/5(Tyr,M1,M2) | Tyrosinase (0.34%) | 5.19 (1.45)a |
2 | A*0201 | A2(+) | 2/5(MART1,gp100) | MART1 (0.64%) | 3.68 (1.49) |
3 | A*2402 | A24(-) | N. Db | N. D. | - |
4 | A*0206 | A2(-) | 2/5(MART1, M2) | - | 3.05 (2.57) |
5 | A*0201 | A2(-) | 2/5(MART1, M2) | MART1 (1.48%) | 2.83 (3.68) |
6 | A*2402 | 2/5(M2,M3), A24(+) | 2/5(M2, M3) | - | 3.76 (2.00) |
7 | A*0201 | 4/5(MART1,Tyr,gp100,M2), A2(+) | 2/5(gp100, M2) | - | 2.64 (1.79) |
8 | A*2402 | A24(-) | N. D. | N. D. | - |
9 | A*0201 | A2(+) | 1/5(gp100)c | N. D. | N. D. |